TOP TEN perturbations for 39328_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39328_at
Selected probe(set): 202540_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39328_at (202540_s_at) across 6431 perturbations tested by GENEVESTIGATOR:

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-4.054037
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)

Relative Expression (log2-ratio):3.599557
Number of Samples:7 / 8
Experimental precursor-B-ALL study 7 (PDX; long-term; >10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis).
Control precursor-B-ALL study 7 (late relapse; >24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

rosuvastatin study 1 (48h) / vehicle (DMSO) treated hepatocyte sample

Relative Expression (log2-ratio):3.5680141
Number of Samples:4 / 6
Experimental rosuvastatin study 1 (48h)
Hepatocytes treated with 10 mmol/l rosuvastatin for 48 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:
Control vehicle (DMSO) treated hepatocyte sample
Hepatocytes treated with vehicle (0.1% DMSO) for 48 hours. Cells were serum deprivated for 48 hours before treatment.

rosuvastatin study 1 (48h) / rifampicin study 5 (48h)

Relative Expression (log2-ratio):3.5282965
Number of Samples:4 / 6
Experimental rosuvastatin study 1 (48h)
Hepatocytes treated with 10 mmol/l rosuvastatin for 48 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:
Control rifampicin study 5 (48h)
Hepatocytes treated with 5 mmol/l rifampicin for 48 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:

R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-3.3039656
Number of Samples:4 / 4
Experimental R547 study 1 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

precursor-B-ALL study 7 (PDX; short-term; <10wk) / precursor-B-ALL study 7 (early relapse; <24m)

Relative Expression (log2-ratio):3.300394
Number of Samples:5 / 22
Experimental precursor-B-ALL study 7 (PDX; short-term; <10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia (B-ALL) generated in NOD/SCID mice with time to manifestation of leukemia (TTL) less than 10 weeks (short-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene,;remision at day 33; non-high risk group; early relapse group (relapse within 24 months from diagnosis).
Control precursor-B-ALL study 7 (early relapse; <24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse within 24 months after diagnosis (early relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-3.2042418
Number of Samples:4 / 4
Experimental R547 study 3 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

DDT study 1 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-3.0292463
Number of Samples:3 / 19
Experimental DDT study 1 (48h)
HepG2 cells exposed to 80μM 1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane (DDT) in DMSO solvent for 48 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.9157953
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

atorvastatin study 3 (48h) / vehicle (DMSO) treated hepatocyte sample

Relative Expression (log2-ratio):2.9027357
Number of Samples:6 / 6
Experimental atorvastatin study 3 (48h)
Hepatocytes treated with 10 mmol/l atorvastatin for 48 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:
Control vehicle (DMSO) treated hepatocyte sample
Hepatocytes treated with vehicle (0.1% DMSO) for 48 hours. Cells were serum deprivated for 48 hours before treatment.